CHICAGO--(BUSINESS WIRE)--March 8, 2004--

Unique Metabolic Profiler(TM) Combines the Complementary Methods of Metabolite Quantitation and Structure Determination by NMR with Exact Mass Analysis by ESI-TOF Mass Spectrometry into an Integrated Metabonomics Solution

At the 2004 Pittsburgh Conference in Chicago, Bruker BioSpin Corporation and Bruker Daltonics Inc. (an operating subsidiary of Bruker BioSciences, NASDAQ: BRKR) today jointly introduce a unique and integrated system for metabolic profiling. This information-rich approach combines the strengths of both nuclear magnetic resonance (NMR) and time-of-flight (TOF) mass spectrometry (MS) into an integrated data acquisition, data evaluation and statistical model building solution for drug development.

The Metabolic Profiler system will be particularly applicable to toxicity and efficacy studies in pre-clinical and clinical development in the pharma and biotech industries. Moreover, this novel combined system is a powerful tool for clinical research in disease screening and patient stratification, with the potential to discover new small molecule diagnostic markers, or panels of metabolic markers.

Whereas genomics and proteomics have received a lot of attention in recent years, the realization that small molecules play an equally important role in the chemistry of biological systems has led to a growing field called metabonomics. The metabolic profile represents a snapshot of on-going biological processes, which has opened the door for the mining of metabolic profiles for biomarkers. The presence of a metabolite, panel of metabolites, or of a certain ratio of metabolites, can be an indication of a particular disease. This creates opportunities for early detection, ideally before the physical symptoms of a disease can be observed.

Metabolic analysis is also a key process in drug development in order to get early pre-clinical indications of efficacy and toxicity. It can be used to detect both the presence of drug metabolites, which may be surrogate markers of efficacy, and it can also detect the presence of certain compounds indicative of, for instance, liver toxicity. It is critical for drug development applications to detect toxicity in the earliest stages of a lead compound development, prior to expensive and time-consuming clinical trials.

The most information-rich techniques currently employed for metabolic profiling today are NMR and MS. On the one hand, NMR spectra of untreated samples represent an overview of all metabolites present in a body fluid. The complete NMR spectrum can be used as a fingerprint, and statistical techniques can be employed for screening purposes. On the other hand, LC/ESI-TOF can perform sensitive exact mass analysis of many metabolites. Following the identification of putative biomarkers, NMR can be used for determining their three-dimensional structure thereby maximizing the understanding of the biological processes. Biomarker discovery companies can use this information-rich combined data to generate defensible intellectual property on metabolites.

Bruker BioSpin and Bruker Daltonics have jointly developed the Metabolic Profiler which combines for the first time in a fully integrated manner the strengths of NMR and ESI-TOF-MS. By integrating an Avance(TM) Flow-NMR system that incorporates a unique 3 mm CryoFlowProbe(TM) (Bruker BioSpin) and the new high-performance microTOF(TM) ESI-TOF mass spectrometer with exact mass capabilities typically better than 3 ppm and a novel Sigma-Fit(TM) isotope pattern verification for automated molecular formula determination (Bruker Daltonics), the Metabolic Profiler represents a comprehensive systems solution for metabolic research and drug development.

Along with the integrated hardware, the Metabolic Profiler provides easy to use software for system control and integrated data evaluation tools from statistics to structure elucidation. NMR and MS spectral databases of reference compounds from all types of bio-fluids can be integrated to allow automatic verification of the presence of specified metabolites. Combining NMR and TOF-MS data in an advanced statistical analysis, visualization and model building information solution offers a new level of selectivity and specificity in metabolic profiling.

John Shockcor, Business Development Manager for Metabolic Profiling of Bruker BioSpin, stated: "The combination of NMR and TOF-MS, the most widely used techniques for metabolic profiling, together with an integrated operating and processing software platform, which includes statistical analysis tools, make the Metabolic Profiler the most complete system for metabonomics research available today."

Frank Laukien, Ph.D., President and CEO of Bruker Daltonics, commented: "The integration of NMR and TOF achieved in the new Metabolic Profiler, provides the most information-rich solution to metabolic research. The integrated statistical methods allow screening for disease detection, as well as for toxicity or drug efficacy. The power of the combined approach allows not only the sensitive molecular formula determination of individual metabolites, both endogenous or derived from drugs, but also benefits from the structural and quantitative strengths of NMR. We believe the integrated Metabolic Profiler will have a major impact on the growing field of metabonomics."

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com.

CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.

ABOUT BRUKER BIOSPIN

Bruker BioSpin Corporation, a member of the global Bruker BioSpin group, designs, manufactures and distributes enabling life science and analytical research tools based on magnetic resonance core technology. The Company's technology platforms include NMR, EPR, MRI, as well as superconducting magnets and superconducting wire. Bruker BioSpin's NMR division is the worldwide technology and market leader in NMR. For more information please visit www.bruker-biospin.com.

CONTACT: Bruker BioSciences Corporation
Michael Willett, 978-663-3660, ext. 1411
ir@bruker-biosciences.com
or
Dahlgren Communications
Jennifer Dahlgren, 530-265-0538
jdahlgren@gv.net
or
Bruker BioSpin Corporation
Brenda Prost, 978-667-9580 ext. 5188
brenda.prost@bruker-biospin.com

SOURCE: Bruker BioSciences